Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance

Tongyan Liu1,3 · Chencheng Han1,2 · Panqi Fang1,5 · Hongyu Zhu1,2 · Siwei Wang1,2 · Zhifei Ma1,2 · Quanli Zhang1,3 · Wenjia Xia1 · Jie Wang1,3,4 · Lin Xu1 · Rong Yin1,3,4

Received: 22 June 2020 / Revised: 15 October 2020 / Accepted: 23 October 2020 / Published online: 10 November 2020
© The Author(s) 2020

Abstract
The efficacy of targeted therapy in non-small-cell lung cancer (NSCLC) has been impeded by various mechanisms of resistance. Besides the mutations in targeted oncogenes, reversible lineage plasticity has recently considered to play a role in the development of tyrosine kinase inhibitors (TKI) resistance in NSCLC. Lineage plasticity enables cells to transfer from one committed developmental pathway to another, and has been a trigger of tumor adaptation to adverse microenvironment conditions including exposure to various therapies. More importantly, besides somatic mutation, lineage plasticity has also been proposed as another source of intratumoural heterogeneity. Lineage plasticity can drive NSCLC cells to a new cell identity which no longer depends on the drug-targeted pathway. Histological transformation and epithelial–mesenchymal transition are two well-known pathways of lineage plasticity-mediated TKI resistance in NSCLC. In the last decade, increased re-biopsy practice upon disease recurrence has increased the recognition of lineage plasticity induced resistance in NSCLC and has improved our understanding of the underlying biology. Long non-coding RNAs (lncRNAs), the dark matter of the genome, are capable of regulating variant malignant processes of NSCLC like the invisible hands. Recent evidence suggests that lncRNAs are involved in TKI resistance in NSCLC, particularly in lineage plasticity-mediated resistance. In this review, we summarize the mechanisms of lncRNAs in regulating lineage plasticity and TKI resistance in NSCLC. We also discuss how understanding these themes can alter therapeutic strategies, including combination therapy approaches to overcome TKI resistance.

Keywords Non-small-cell lung cancer · Tyrosine kinase inhibitors · Long non-coding RNAs · Lineage plasticity

Abbreviations
NSCLC Non-small-cell lung cancer
lncRNA Long non-coding RNA
TKI Tyrosine kinase inhibitors
EGFR Epidermal growth factor receptor
BRAF Serine/threonine-protein kinase b-raf
ALK Anaplastic lymphoma kinase
TME Tumor microenvironment
EZH2 Enhancer of zeste homolog 2
ATL-1 Atractylodes macrocephula Koidz atractylanolide 1
STAT3 Signal transducer and activator of transcription
PI3K Phosphatidylinositol 3-kinase

Rong Yin
rong_yin@njmu.edu.cn

1 Department of Thoracic Surgery, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China
2 The Fourth Clinical College of Nanjing Medical University, Nanjing, China
3 Department of Scientific Research, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, China
4 Jiangsu Biobank of Clinical Resources, Nanjing 210009, China
5 Department of Clinical Pharmacy, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China
SCLC  Small-cell lung cancer  
EMT  Epithelial-to-mesenchymal transition  
NCAM1  Neural cell adhesion molecule 1  
RB1  RB transcriptional corepressor 1  
TP53  Tumor protein p53  
CRPC  Castration-resistant prostate cancer  
AR  Androgen receptor  
NEPC  Neuroendocrine prostate cancer  
ZEB  Zinc finger E-box-binding homeobox  
TGFβ  Transforming growth factor-β  
IL-6  Interleukin 6  
LSD1  Lysine-specific demethylase 1  
DNMT1  DNA methyltransferase 1  
CDKN1A  Cyclin-dependent kinase inhibitor 1A  
YAP1  Yes-associated protein 1  
PRC2  Polycomb repressive complex 2  
REST  RE1-silencing transcription factor  
TFBS  Transcription factor binding site  
LUAD  Lung adenocarcinoma  
E2F1  E2F transcription factor 1  
INSM1  Insulinoma-associated-1  
ASCL  Achaete-scute complex homolog 1  
ASH1  Achaete-scute homolog 1  
CAF  Cancer-associated fibroblast  
HGF  Hepatocyte growth factor  
MET  Mesenchymal–epithelial transition factor receptor  
GAS6  Growth arrest specific 6  
EGF  Epidermal growth factor  
HB-EGF  EGF-like growth factor  
ECM  Extracellular matrix  
CXCL12  CXC-chemokine ligand 12  
TAM  Tumor-associated macrophage  
MAPK  Mitogen activated kinase-like protein  
NF-κB  Nuclear factor kappa B  
RAS  Resistance to audiogenic seizures (RAS)  
COX2  Cytochrome oxidase subunit II  
PGE2  Nr5a1 enhancer region in intron 6  
HIF1α  Hypoxia-inducible factor 1α  
VEGF  Vascular endothelial growth factor  
PDL1  Programmed cell death 1 ligand 1  
HDAC  Type-2 histone deacetylase 2  
H3K9me3  Trimethylation of lysine 9 on histone  

Introduction

Lung cancer is the leading cause of cancer-associated mortality worldwide, with non-small-cell lung cancer (NSCLC) as the main histological subtype with a poor 5 year survival [1]. Improved understanding of the molecular classification of lung cancer has revolutionized the treatment of NSCLC. Almost two-thirds of patients with NSCLC are oncogene addicted, approximately half of whom are exquisitely sensitive to targeted therapies [2, 3]. These include activating mutations or fusions in epidermal growth factor receptor (EGFR), serine/threonine-protein kinase b-raf (BRAF), anaplastic lymphoma kinase (ALK), and ROS1 receptor tyrosine kinase [3].

Although agents that target the tyrosine kinase domain of these oncogenes improve clinical outcomes of patients with NSCLC, responses to these drugs are generally temporary and limited by emergence of resistance [4]. Resistance to tyrosine kinase inhibitors (TKI) are generally associated with acquired somatic mutations, including genetic alterations that enable bypassing target inhibition through ineffective binding of the drugs, as well as activation of collateral or alternative survival pathways [3, 5, 6]. In addition to these genetic mechanisms of drug resistance, non-mutational mechanisms termed lineage plasticity are also associated with TKI resistance. Lineage plasticity refers to the ability of cells transferring from one committed developmental pathway to another. It enables the adaptation and survival of tumors under adverse conditions including hypoxia and targeted therapies. Therefore, it is proposed as a mechanism of tumor cells escape from targeted dependency. Lineage plasticity can be both dependent on and a driver of intratumoral heterogeneity [7, 8]. In contrast to genetic mechanisms of TKI resistance, lineage plasticity-associated resistance primarily relies on phenotype switching, with one single genotype gives rise to different phenotypes upon drug treatment. It enables cancer cells to reversibly convert to new or hybrid lineages that is independent of TKI-targeted pathway [9].

Data from single-cell profiling and lineage tracing technologies suggest that a single cell can give rise to multiple states. Mechanistically, epigenetic modifications and transcriptional transitions may mediate the emergence of new cell states. Long non-coding RNAs (lncRNAs) the dark matter of the genome, are capable of regulating variant malignant processes of NSCLC through epigenetic modification [10]. Importantly, lncRNAs often offer distinct advantages over proteins for some forms of epigenetic regulation [11]. Recent studies show the transcriptional heterogeneity regulated by lncRNAs might drive the phenotypic switch from one histological category to another, contributing to the lineage plasticity-mediated TKI resistance.

Targeting lineage plasticity provides a new opportunity to prevent the emergence of drug-tolerant cell states and enables TKI to achieve deeper responses. In this review, we performed a literature review covering the publication of the last 15 years on the topic of “long non-coding RNAs regulated lineage plasticity in lung cancer”. The keywords used for searching were “cell plasticity”, “cancer” and “non-coding RNAs”. We summarize current understanding of lineage plasticity as a mechanism of TKI resistance in NSCLC and discuss the implications of lncRNAs in lineage plasticity.
Finally, we also discuss potential therapeutic strategies to circumvent lineage plasticity in NSCLC.

**Lineage plasticity in response to targeted therapies**

Lineage plasticity, the ability of cells to reversibly transfer from a certain developmental pathway to another, has been regarded as a source of intratumoral heterogeneity and of tumor adaptation to adverse tumor microenvironment such as hypoxia and exposure to targeted therapies [7]. Histological transformation of adenocarcinomas to neuroendocrine and epithelial–mesenchymal transition are two well-known phenotypes of lineage plasticity in NSCLC upon TKI treatment [7, 12]. NSCLC cells has been reported to hijack developmental process involved in epigenetic modification and transcriptional reprogramming to become phenotypically plastic, and reversibly transform into one or several drug-tolerant cell identities [13, 14]. Interestingly, the emergence of slow-cycling tumors cells is primarily considered as the first state before histological transformation and further reprogramming into a drug-resistant state [15, 16]. Adenocarcinomas with concomitant inactivation of RB1 and TP53 are more likely to transdifferentiate into neuroendocrine tumors in NSCLC [17–20]. Furthermore, loss of lung lineage-specifying transcription factor gene Nkx2-1, overexpression of lineage-specific transcription factors such as SOX genes, and dysregulation of epigenetic regulators such as histone methyltransferase, changes of key signaling pathways (IL-6-STAT3 or RXR, etc.), as well as interactions with tumor microenvironment (TME) have been associated with intratumoural heterogeneity and lineage plasticity-mediated drug resistance [7, 14] (Fig. 1).

**Histological transformation**

Histological transformation also referred to as transdifferentiation, which presents the process that cells convert from one lineage to another [21]. Targeted therapy-induced neuroendocrine transdifferentiation has been particularly described in NSCLC and prostate cancer [12, 22]. The transformation of EGFR-mutant adenocarcinoma to a SCLC histology was first reported in a 45-year-old woman with EGFR-mutant adenocarcinoma who underwent erlotinib treatment for 18 months before relapse with the features of SCLC, and positive immunostaining of neural cell adhesion molecule 1 (NCAM1), chromogranin A and synaptophysin [23]. In rare cases, NSCLC could adopt to other neuroendocrine histology, for instance, large cell neuroendocrine carcinoma and small and large cell carcinoma [19]. Transformation to sarcomatoid carcinoma has also been observed in ALK-rearranged NSCLC in resistant to crizotinib. Importantly, the transformed SCLC tumor samples maintained their original mutation [23], which indicates these tumors were emerging from the original adenocarcinoma, rather than de novo cancers. Genetically, NSCLC cells with RB1 and TP53 loss are more likely to transdifferentiate towards a neuroendocrine identity upon TKI treatment [17, 18]. Similiar observations were made in castration-resistant prostate cancer (CRPC), with approximately one-quarter of CRPC acquire androgen receptor (AR) independent resistant through phenotypic switching [22]. These AR-independent
CRPC tumors are referred to as neuroendocrine prostate cancer (NEPC) [22].

**Epithelial–mesenchymal transition**

Epithelial–mesenchymal transition (EMT) is another type of tumor cell plasticity related to TKI resistance [12, 24], which tumor cells lose their epithelial features and acquire cellular alterations favoring more invasive, mesenchymal properties. Mesenchymal characteristics were observed in vitro and in vivo EGFR-mutant lung cancer models that acquired resistance to first-generation EGFR-TKI with no genetic alterations [25, 26]. Moreover, tumor biopsy samples from EGFR-TKI resistance patients presented increased vimentin expression and downregulated E-cadherin expression compared with tumor tissues taken before TKI treatment. Importantly, tumor cells undergo epithelial–mesenchymal plasticity retain their original mutation spectrum, indicating EMT as a mechanism of TKI resistance [12, 27]. The precise mechanism of epithelial–mesenchymal plasticity remains to be elucidated. Increased levels of pleiotropic signaling factors, such as transforming growth factor-β (TGF-β), epidermal growth factor (EGF), hepatocyte growth factor (HGF), NOTCH, fibroblast growth factor (FGF) and WNT ligands can initiate a signaling cascade resulting the expression of EMT associated genes, such as zinc finger E-box binding protein-1 and 2 (ZEB1 and ZEB2), thereby initiate EMT in NSCLC [39–46]. Increased levels of transforming growth factor-β (TGFβ) are reported to facilitate EMT via interleukin-6 (IL-6) in EGFR TKI-resistant NSCLC cells [47]. Several profiling studies have identified the roles of TGFβ-regulated lncRNAs such as ELIT-1, TIBILA, LINP and HOTAIR in promoting EMT in NSCLC cell lines [48–51]. Mechanistically, TGFβ-activated lncRNA ELIT-1 can bound to Smad3 and improved Smad-responsive promoter activities by recruiting Smad3 to the promoters of its target genes, which include Snail, and ELIT itself. Thus, ELIT-1 forms a positive feedback loop to promote TGFβ/Smad3 signaling pathway and, therefore, promote EMT progression [48]. NORAD, a cytoplasmic long non-coding RNA is also reported to promote TGFβ-induced EMT in NSCLC cell lines [52]. It is shown to enhance the physical interaction of importin β1 with Smads, thereby promoting the nuclear accumulation of Smad complexes induced by TGFβ. Furthermore, many lncRNAs associate with epigenetic regulators to regulate EMT. For instance, lncRNA MEG3 is able to recruit EZH2 and epigenetically silencing CDH1 and miR-200 family in NSCLC cell lines [53]. Similarly, MALAT1 can also recruit EZH2 to silence E-cadherin and, therefore, induce EMT in NSCLC [54]. LncRNA-FEZF1-AS1 was shown to epigenetically repress E-cadherin by binding with lysine-specific histone demethylase 1 (LSD1) and EZH2 in NSCLC cells [55]. HOXA11-AS1 was reported to recruit EZH2 and DNA methyltransferase 1 (DNMT1) to the promoter of miR200b and inactivate miR200b, thereby promoting EMT in NSCLC [56]. In contrast, a number of epigenetic upregulated lncRNAs can inhibit EMT through histone modification in NSCLC [57, 58]. For example, lncRNA-BANCRC inhibits EMT through histone acetylation [58]. Most TGFβ-regulated lncRNA were reported to

**EMT-associated lncRNAs**

EMT is a dynamic process which tumor cells obtain phenotypic changes through epigenetic modifications [36]. Emerging evidence highlights the involvement of lncRNAs in EMT process in NSCLC [37].

Recently, a group of lncRNAs have been shown to promote drug resistance by acting as molecular decoys to sequester miRNAs associated with EMT. For example, LINC00673, CAR10, XIST, LINC81507, TTANAS1, LINC00858, H19, SOX20T, LINC00483, PRNCR1, SNHG6, ATB and alternative splicing-generated lncRNA-PNUTS [38] are shown to sequester miRNAs from binding EMT associated genes, such as zinc finger E-box binding protein-1 and 2 (ZEB1 and ZEB2), thereby initiate EMT in NSCLC [39–46]. Increased levels of transforming growth factor-β (TGFβ) are reported to facilitate EMT via interleukin-6 (IL-6) in EGFR TKI-resistant NSCLC cells [47]. Several profiling studies have identified the roles of TGFβ-regulated lncRNAs such as ELIT-1, TIBILA, LINP and HOTAIR in promoting EMT in NSCLC cell lines [48–51]. Mechanistically, TGFβ-activated lncRNA ELIT-1 can bound to Smad3 and improved Smad-responsive promoter activities by recruiting Smad3 to the promoters of its target genes, which include Snail, and ELIT itself. Thus, ELIT-1 forms a positive feedback loop to promote TGFβ/Smad3 signaling pathway and, therefore, promote EMT progression [48]. NORAD, a cytoplasmic long non-coding RNA is also reported to promote TGFβ-induced EMT in NSCLC cell lines [52]. It is shown to enhance the physical interaction of importin β1 with Smads, thereby promoting the nuclear accumulation of Smad complexes induced by TGFβ. Furthermore, many lncRNAs associate with epigenetic regulators to regulate EMT. For instance, lncRNA MEG3 is able to recruit EZH2 and epigenetically silencing CDH1 and miR-200 family in NSCLC cell lines [53]. Similarly, MALAT1 can also recruit EZH2 to silence E-cadherin and, therefore, induce EMT in NSCLC [54]. LncRNA-FEZF1-AS1 was shown to epigenetically repress E-cadherin by binding with lysine-specific histone demethylase 1 (LSD1) and EZH2 in NSCLC cells [55]. HOXA11-AS1 was reported to recruit EZH2 and DNA methyltransferase 1 (DNMT1) to the promoter of miR200b and inactivate miR200b, thereby promoting EMT in NSCLC [56]. In contrast, a number of epigenetic upregulated lncRNAs can inhibit EMT through histone modification in NSCLC [57, 58]. For example, lncRNA-BANCRC inhibits EMT through histone acetylation [58]. Most TGFβ-regulated lncRNA were reported to
### Table 1 Examples of lncRNAs implicated in lineage plasticity in NSCLC

| lncRNA                          | Association with Cancer | Function                                                                 | Cellular phenotypes                  | Refs |
|---------------------------------|-------------------------|--------------------------------------------------------------------------|--------------------------------------|------|
| Slow cycling                    |                         |                                                                         |                                      |      |
| lincRNA-p21, LED                | p53-induced lncRNAs     | Protein interactions (interaction with hnRNPK to regulate CDKN1A; interaction with CDKN1A enhancer | Cell-cycle arrest                     | [61] |
| LINC-PINT, TUG1, PR-lncRNA-1, PR-lnRNA-10 | p53-induced lncRNAs | Connects p53 pathway with epigenetic silencing by PRC2                   | Cell-cycle arrest                     | [61] |
| p15-AS1, MIR31HG, MIR100HG      | Downregulated in lung cancer | Silencing of p15 through heterochromatin formation; Protein interactions (decoy for polycomb group proteins to repress INK4A transcription) | Growth arrest and apoptosis           | [65, 66] |
| MALAT1, CASC2, TINCR            | Downregulated in lung cancer | Chromatin condensation by recruitment of PRC2                          | Growth arrest                         | [68] |
| EMT                             |                         |                                                                         |                                      |      |
| LINC00673, CAR10, XIST, LINC81507, LINC TTN-AS1, LINC00858, H19, SOX20t1, LINC00483, PRNCR1, SNHG6, ATB, PUNUTS | Overexpressed in lung cancer | miRNA decoy (for miR200, miR181a) | EMT, invasion, proliferation and metastasis, drug resistance | [35] |
| ELIT-1, TBILA, LINP, HOTAIR,NKILA and LINC001186 | TGFβ-regulated lncRNAs | Interacts with various proteins; interferes with different signaling pathway | EMT, metastasis                      | [45–48, 56, 57] |
| MEG3                            | Overexpressed in NSCLC cells | Chromatin condensation by recruitment of EZH2 to silence E-cadherin and miR-200 family | EMT, metastasis                      | [50] |
| MALAT1                          | Overexpressed in lung cancer | Chromatin condensation by recruitment of EZH2 to silence E-cadherin     | EMT, metastasis                      | [51] |
| FEZF1-AS1                       | Overexpressed in lung cancer | Chromatin condensation by recruitment of LSD1 and EZH2 to repress E-cadherin | EMT, metastasis                      | [52] |
| HOXA11-AS1                      | Overexpressed in lung cancer | Gene methylation by recruitment of EZH2 and DNMT1 to inactivate miR200b | EMT, metastasis                      | [53] |
| NORAD                           | Overexpressed in lung cancer | Molecular scaffold for proteins (importin β1 and Smads)                  | EMT, metastasis                      | [49] |
| Epigenetic reprogramming        |                         |                                                                         |                                      |      |
| HOXA11-AS                       | Overexpressed in NSCLC | Chromatin condensation by recruitment of PRC2 to silence miR200          | EMT, tumor progression                | [53] |
| FBXL19-AS1                      | Overexpressed in LUAD | miRNA Decoy (for miR-203a-3p), enhances E2F and ZEB1                     | Proliferation, migration and metastasis | [76] |
| Reprogramming transcription factors |                         |                                                                         |                                      |      |
| SOX2-OT                         | Overexpressed in lung cancer | Regulation the expression of SOX2                                       | Neural differentiation                | [81, 82] |
| Key signaling pathways          |                         |                                                                         |                                      |      |
| SNHG1                           | Overexpressed in cisplatin-resistant NSCLC | miRNA Decoy (for miR140-5p), increases WNT/β-catenin pathway             | Neural differentiation, drug resistance | [90] |
Mechanisms of lncRNA-mediated lineage plasticity

The molecular mechanisms underlying lineage plasticity-mediated TKI resistance remain to be fully established. However, tumor cells go through a slow-cycling drug-tolerant state is generally considered as the first step for lineage plasticity-mediated resistance. Moreover, epigenetic and transcription factor changes and alterations of key signaling pathways, as well as crosstalk with tumor microenvironment (TME) can favor the development of phenotypic switching and TKI resistance (Fig. 2).

Emergence of slow-cycling cells

A drug-tolerant, slow-cycling state was first identified in bacteria [61]. In that scenario, a group of drug-tolerant slow-cycling bacteria survive in response to antibiotic treatment, and can further convert to a proliferative state and re-established drug sensitive phenotype upon drug withdrawal [61]. Similarly, reversible drug-tolerant slow-cycling persisters were reported in NSCLC. Notably, a stepwise transition may occur in NSCLC upon TKI treatment, tumor cells first reversibly enter a slow-cycling state, then regain proliferation and ultimately become drug-resistant through further epigenetic changes or via genetic modifications (such as EGFR-T790M) [6, 15]. More recently, Sanchez-Danes et al. also discovered that in basal cell carcinoma, drug-tolerant slow-cycling residuals cells can lead to relapse upon drug withdrawal [62]. Forcing these slow-cycling cells to proliferate enhanced their sensitivity to vismodegib treatment, which lead to their elimination [62].

LncRNAs involved in regulating cell-cycling conditions in cancer are primarily defined as p53-related lncRNAs [63]. Genome-wide profiling of p53-regulated enhancer RNAs identified p53-induced lincRNA-p21, LINC-PINT, MALAT1, FOXO2-AS1, and TUG1, which may support cell-cycle arrest [63]. Mechanistically, lincRNA-p21 bound to heterogeneous nuclear ribonucleoprotein K (hnRNP K) to regulate cyclin-dependent kinase inhibitor 1A (CDKN1A) is cis and arrest the cell cycle [64]. Another p53-induced lncRNA DINO was shown to interact with p53 protein and enhanced its stabilization, creating a p53 auto-amplification loop, thereby promoting damage signaling pathway and cell cycle arrest in the absence of DNA damage [65]. Moreover, alterations in cell cycle
proteins, including the silencing of cyclin dependent kinase (CDK) inhibitor p16 and p15 are associated with resistance to EGFR TKI in NSCLC patients [66]. Several lncRNAs such as p15-AS-1 and MIR31HG can suppress p15 or p16 through heterochromatin formation [67, 68]. Moreover, MIR100HG encoded lncRNA interacts with HuR/ELAVL1 as well as several HuR-target genes (oncogenes) to suppress cell proliferation [69]. In addition, lncRNA TINCR, CASC2, MALAT1 were involved in FBXW7-mediated cell cycle arrest in various cancers [70]. Nevertheless, it remains to be elucidated whether these cell cycle-associated lncRNAs are implicated in the drug-tolerant refractory cells under the pressure of TKI.

It is important to note that most of these studies are conducted in vitro, and should in the future, be further validated in vivo.

**Epigenetic modification**

The histone methyltransferase EZH2, which is the catalytic subunit of Polycomb repressive complex 2 (PRC2), is reported to promote neuroendocrine transdifferentiation in a mouse model of lung cancer [71]. Similarly, EZH2 is also a well-established feature of NEPC [31, 72]. Pharmacological or genetic inhibition of EZH2 activity in NEPC cell lines can reverse its lineage conversion and regain drug
sensitivity [30, 31, 73] RE1-silenicng transcription factor (REST), another epigenetic regulator, is found in lung and prostate cancer during neuroendocrine conversion [74, 75]. REST suppresses gene expression generally through recruiting the co-repressors such as EZH2 [75]. Elevated levels of REST are reported to promote neuroendocrine differentiation in EGFR TKI resistance NSCLC cell lines via Notch signaling pathway [76].

Many IncRNAs have been shown to scaffold and recruit epigenetic regulator to specific genome loci. For example, IncRNAs HOXA11-AS can recruit PRC2 complex to silence miR200b [56]. On the other hand, a few IncRNAs are regulated by E2F transcription factor 1 (E2F1), which is a transcription factor that induce EZH2 expression [77]. Transcription factor-binding site (TFBS) analysis identified IncRNAs FENDRR, H19, LINC00514, LINC00617 and STR5-AS1 include TFBS motifs for REST and E2F, and the expression of these IncRNAs were implicated in the development of NEPC [35]. Furthermore, FBXL19-AS1/miR-203a-3p axis was found to enhance E2F1 and ZEB1 in lung adenocarcinomas (LUAD) cells [78]. Therefore, IncRNAs are important players in scaffolding EZH2-dependent gene silencing and subsequent regulate EZH2-mediated phenotypic switching.

**SOX family members**

Several lineage-specific transcription factors are involved in lineage plasticity and drug escape both in NSCLC and prostate cancer. The SOX family is important in regulating cell fate decisions and is implicated in phenotypic conversion in various cancer models [79]. For instance, the expression of SOX2 was increased in TP53 and RB1-deficient GEMMs and xenograft models of LUAD and prostate cancers [30, 31]. Moreover, the neural lineage-specific factor BRN2, which is specifically expressed in SCLC and NEPC tumors, mediates SOX2 expression and is key for neuroendocrine transformation [80, 81]. Furthermore, insulinoma-associated-1 (INSM1), which encodes a zinc-finger transcription factor, has recently emerged as a specific neuroendocrine transcription factor and a sensitive biomarker for neuroendocrine tumors [82].

LncRNA SOX2 overlapping transcript (SOX2-OT) are functionally assumed to be associated with neuronal like differentiation and carcinogenesis [83, 84]. Concordant expression of SOX2 and SOX2-OT is found in lung and breast cancer [83]. Notably, SOX2-OT can generate six transcript variants in different cancer models [85, 86], and have been proposed to play a role in regulating the expression of SOX2 [84, 85]. Collectively, SOX reprogramming factors, together with other lineage-associated transcription factors, are key for cellular plasticity in TKI resistant NSCLC cells. LncRNA-SOX2-OT, as SOX2 overlapping transcript also makes contribution for promoting the transition toward neural crest state in NSCLC.

**Key signaling pathways**

Several signaling pathways play a part in phenotypic switching upon TKI treatment. The activation of WNT/β-catenin pathway is reported to promote neuroendocrine differentiation in various cancer models [87]. Meder et al. discovered NOTCH-Achaete-scute complex homolog 1 (ASCL)-WNT signaling pathway could inactivate RB by phosphorylation and, therefore, promote neuroendocrine differentiation in NSCLC [88, 89]. Moreover, achaete-scute homolog 1 (ASH1) also acts as a positive regulator of WNT/β-catenin pathway, transforming NSCLC into a SCLC phenotype with neuroendocrine features both in vitro and in vivo models [90]. A number of IncRNAs have been found to active WNT/β-catenin to induce EMT and therapy resistance in NSCLC [91–93]. For instance, IncRNA-SNHG1 can sequester miR140-5p from binding WNT to active WNT/β-catenin signaling in NSCLC [92]. LINC00673 functions as a modulatory scaffold to strengthen the interaction between DDX3 and CK1ε, induces phosphorylation of Dvl and, therefore, promote the nuclear accumulation of β-catenin and the activation of WNT/β-catenin signaling pathway in LUAD [93]. Furthermore, the expressions of IncRNA-NEAT1, FOXO2-AS1 were positively associated with WNT/β-catenin signaling in NSCLC [91–93]. For instance, IncRNA-SNHG1 can sequester miR140-5p from binding WNT to active WNT/β-catenin signaling in NSCLC [92]. LINC00673 functions as a modulatory scaffold to strengthen the interaction between DDX3 and CK1ε, induces phosphorylation of Dvl and, therefore, promote the nuclear accumulation of β-catenin and the activation of WNT/β-catenin signaling pathway in LUAD [93].

**IL-6-STAT3 axis** is also activated upon EGFR TKI treatment and can promote neuroendocrine differentiation in NSCLC [96]. LncRNAs such as MALAT1 and H19 are reported to, respectively, sponge miR-124, miR-17 and miR-29b-3p, subsequently activated STAT3 and promote therapy resistance [97–99]. In addition, Wang et al. showed lncRNA TNK2-AS1 was significantly upregulated in NSCLC and associated with poor survival. Mechanistically, TNK2-AS1 could interact with STAT3 to enhance its protein stability, on the other hand, STAT3 also triggers the transcription of TNK2-AS1. Thus, the positive feedback loop between TNK2-AS1 and STAT3 augmented STAT3 signaling pathway in NSCLC [100].

**The tumor microenvironment**

The tumor microenvironment (TME) is a multicellular system with dynamic tumor-stromal component interactions [101, 102]. Altogether, the various stromal components such as fibroblasts, endothelial cells and infiltrating immune cells influence the response to TKI therapy.

It is well established that cancer-associated fibroblasts (CAFs) can induce EMT and TKI resistance in NSCLC...
cells in vitro [103, 104]. The secretion of soluble factors such as hepatocyte growth factor (HGF) promoted MET or ERK activation and subsequent EGFR TKI resistance in NSCLC cells [105, 106]. CAFs can also derive the AXL ligand growth arrest-specific protein 6 (GAS6) and enhance the expression of anti-apoptotic gene BCL2, leading to TKI resistance [26, 107].

The extracellular matrix (ECM) also interacts with NSCLC cells to promote drug tolerance. A study in 3D lung cancer cell models revealed that ECM-induced ERK and PI3K/AKT signaling lead to an EGFR TKI tolerant dormant state [108]. Low levels of SerpinB2 (a serine protease inhibitor that increase ECM stiffness), is negatively associated with gefitinib resistance in vitro. And treatment with a SerpinB2-inducing agent reversed the drug-tolerant state [108]. Moreover, Elevated levels of N-cadherin and integrinβ could promote tumor cells adhesion to ECM, thereby, promoting EGFR TKI resistance [109].

Tumor-associated macrophages (TAMs) are important infiltrating immune cells with crucial role in the development of TKI resistance [110]. Patients with increased TAM infiltration within the TME had poor outcomes [111]. Computational modelling of RNA expression in a mouse model of NSCLC revealed TAMs-secreted factors can activate various signaling pathways related to EGFR TKI resistance, including the MAPK, YAP, NF-κB, PI3K, WNT and RAS pathways [112]. Furthermore, macrophage could promote EMT through the IL-6-mediated COX2/PGE2/β-catenin signaling pathway [113]. Notably, a few lncRNAs such as GNAS-AS1 and XIST are reported to promote macrophage M2 polarization in NSCLC and, therefore, play a part in TAM-induced drug tolerant [114, 115].

Finally, hypoxia and the density and distribution of vasculature are closely associated with EGFR TKI resistance. Hypoxia-inducible factor 1α (HIF1α) promotes TKI resistance in a TGFα-dependent manner and increases cancer stem phenotype via IGF1R activation [116, 117]. In addition, the secretion of vascular endothelial growth factor (VEGF) by endothelial cells under hypoxia promotes angiogenesis and drug resistance [118]. Additionally, the expression of immune checkpoint programmed cell death 1 ligand 1 (PD-L1) can be upregulated in some EGFR-mutated or ALK-rearranged NSCLC patients. A preliminary study has found the combination of PD-L1 nanobody and gefitinib displayed effectiveness of reversing the gefitinib resistance in NSCLC [119]. However, the extent of TME contributes to TKI resistance and the involvement of lncRNAs in TME-mediated resistance warrants further investigation, particularly as novel therapies that target immune and stromal cells continue to emerge. The emerging challenge is to clarify whether there is potential for therapeutic synergy between immunotherapy and targeted therapy in preventing lineage plasticity and TKI resistance.

### Targeting strategies for lineage plasticity

#### Targeting epigenetic regulators

Since certain epigenetic alterations are correlated with slow-cycling drug-tolerant cells, targeting the potential epigenetic regulators serves as an important way to ameliorate lineage plasticity. Notably, preventing phenotypic switching by targeting HDAC or histone demethylases KDM5A/B and KDM6A/B have promising results in early-phase studies [120]. In NSCLC, trimethylation of lysine 9 on histone (H3K9me3) represses long-interspersed repeat elements 1 (LINE-1), thus inhibiting the expression of interferon and antiviral-activated genes to promote EGFR TKI-tolerant cell survival [121, 122]. HDAC inhibitor trichostatin A or entinostat counterbalanced the drug-tolerant cells via suppressing LINE [121]. Early-phase studies of detecting HDAC inhibitors in combination with EGFR TKI are ongoing. Inhibiting demethylases KDM6 with GSK-J4 suppressed residual persister cells in glioblastoma [123, 124], (Table 2).

EZH2 is another druggable epigenetic regulator as mentioned previously [72]. Several phase I and phase II clinical trials are ongoing to inhibit EZH2 in lymphomas and multiple solid tumors [125, 126]. In a mouse model of human LUAD, using an open-source EZH2 inhibitor JQEZ5, Zhang et al. have established efficient antitumor effects [127, 128]. Another study has found that EZH2 inhibitor GSK343 synergy with gefitinib in NSCLC cells [129]. However, EZH2 inhibitor GSK2816126 failed in another early phase II trial in patients with similar indications [14]. Assessment of other epigenetic regulators, such as REST, are also ongoing. In addition, the dual HDAC and 3-hydroxy-3-methylgutaryl coenzyme A reductase inhibitor, JMF3086, which regulate the post-translational regulation of E-cadherin, can restore the sensitivity to first and third-generation EGFR-TKI in NSCLC [130]. (Fig. 3).

Numerous mechanistic studies support the hypothesis that targeting epigenetic regulators can synergize with TKI agents and reverse lineage plasticity in preclinical models. Nevertheless, the efficacy of epi-drugs tested in clinical trials to date has been disappointing. Overall, the epigenetic modulators exert broadening effects on cell biology and systemic physiology. Inhibitors targeting epigenetic regulators might lead to the dysregulation of cell biology [131, 132]. Therefore, novel agents are needed to target lineage plasticity more specifically. LncRNAs are excellent candidates in this respect. Several features of IncRNAs render their potential therapeutic targets in lineage plasticity-mediated TKI resistance. First, the expression of IncRNAs show strong conservation of tissue specificity [133]. Interestingly, many IncRNAs are patient and
The exclusive expression pattern of lncRNAs in specific types of tissues or cells provides an opportunity for specific regulation by lncRNA-targeting therapeutics [133, 135]. Second, chromatin modification represents an important mechanism for lncRNA, thus targeting the interaction of lncRNAs with epigenetic factors such as EZH2 can be envisioned. Third, many nuclear lncRNAs regulate neighboring gene expression in cis, thus locus-specific regulation can be achieved through lncRNA manipulation. However, the development of lncRNA therapeutics is still in its infancy. Traditional RNAi has proven generally ineffective for lncRNA, due to their unique localization and expression [136]. Currently, antisense oligonucleotides (ASOs) and CRISPR-Cas9 are considered as promising approaches to target lncRNAs [137, 138]. Furthermore, we anticipate that future pooled CRISPR screening will be implemented to identify lineage plasticity-related lncRNAs. Nevertheless, we are beginning to understand the roles of lncRNAs in lineage plasticity. Targeting lineage plasticity associated lncRNAs in combination with TKI treatment has not been reported yet. Further translation research and clinical trials are needed.

### Table 2: Selected clinical NSCLC trials of targets and compound targeting lineage plasticity

| Drug regimen                  | Phase | Identification                          | Results                                      | Chilicaltrials.gov identifier | Refs |
|-------------------------------|-------|----------------------------------------|---------------------------------------------|-------------------------------|------|
| HDAC inhibitor                |       |                                        |                                             |                               |      |
| Vorinostat+ gefitinib         | I/II  | Relapsed/refractory advanced NSCLC     | No improvement in PFS                       | NCT01027676                  | [120]|
| Vorinostat+ erlotinib         | I/II  | Relapsed EGFR-mutant NSCLC             | No improvement in erlotinib-resistant population | NCT00503971                  | [120]|
| Belinostat+ Erlotinib         | I     | Molecularly unselected                 | Results pending                            | NCT01027676                  | [120]|
| SNDX-275 + Erlotinib          | II    | Progression on erlotinib               | Results pending                            | NCT00750698                  | [120]|
| KDM5 and KDM6                |       |                                        |                                             |                               |      |
| YUKA1, CPI-455 (KDM5A specific), KDOAM-25 (KDM5A-D specific) + gefitinib | Preclinical | EGFR-mutant NSCLC | YUKA1 in combination with gefitinib prevents drug tolerance in EFGR-mutant NSCLC | [123, 124] |      |
| CDK7/12                      |       |                                        |                                             |                               |      |
| SY-1365                      | I     | Advanced solid tumors                  | Ongoing                                    | NCT03134638                  |      |
| AXL inhibitor                |       |                                        |                                             |                               |      |
| BGB324 + erlotinib           | II    | Molecularly unselected NSCLC           | First efficacy end point met               | NCT02424617                  | [141]|
| SGI-7079 + erlotinib         | Preclinical | Molecularly unselected NSCLC | Enhanced sensitivity of mesenchymal-like NSCLC cells to erlotinib | [25] |      |
| TP-0903                      | Ia/Ib | Advanced solid tumors                  | Ongoing                                    | NCT02729298                  |      |
| E-cadherin                   |       |                                        |                                             |                               |      |
| JMF3086                      | Preclinical | Molecularly unselected NSCLC | Restore sensitivity to EGFR-TKI | [130] |      |
| EZH2 inhibitor               |       |                                        |                                             |                               |      |
| JQEZ5                        | Preclinical | EGFR or BRG1-mutant NSCLC | Decreased tumor burden in GEMM and human NSCLC models | [127, 128] |      |
| GSK343 + gefitinib           | Preclinical | NSCLC | Inhibited cell viability | [129] |      |

**NSCLC** non-small-cell lung cancer, **EGFR** epidermal growth factor receptor, **HDAC** histone deacetylase, **PFS** progression-free survival, **KDM** histone demethylase, **RXR** retinoid X receptor, **EZH2** zeste homologue 2, **IL-6** interleukin-6, **AXL** receptor tyrosine kinase, **TKI** tyrosine kinase inhibitors

In addition to targeting epigenetic regulators involving in lineage plasticity, it is also appealing to target the emerging drug-tolerant cell identity. There are ongoing efforts to evaluate whether NSCLC that have undergone neuroendocrine differentiation share similar treatment schedules with de novo SCLC. Notably, transformed SCLC presented sensitivity to palatum-etoposide, which makes them more similar to de novo SCLC [139]. However, it is important to note that a contrasting result came from another retrospective study, in which transformed SCLC patients still displayed higher responsive to taxanes than de novo SCLC but failed response to checkpoint inhibitor...
Therefore, treatment regimens on transformed SCLC need to be cautiously evaluated and await further functional investigation. Interestingly, our previous study demonstrated certain non-coding RNA could facilitate the therapeutic effects of EGFR-TKI in NSCLC [140]. Our unpublished data also showed that a few IncRNAs are crucial for the transformation from NSCLC to SCLC in response to TKI treatment and could be targeted to prevent lineage plasticity. Therefore, IncRNAs involving in the histological transformation will be worthwhile areas for further investigation.

EMT represents an important process determining new cell fate of cancer. The correlation between the expression of EMT signature and receptor tyrosine kinase AXL in NSCLC indicates that AXL may represent a novel target [25]. Notably, combination of AXL inhibitor SGI-7079 with EGFR TKI erlotinib increased the sensitivity of mesenchymal-like tumor cells to erlotinib in a mouse xenograft NSCLC model [25]. Preliminary findings also suggest that BGB324, the first AXL-specific-molecule inhibitor approved for clinic, can be safely administered, resulting in disease stabilization in a group of NSCLC patients [141].

**Conclusion**

Along with genetic alterations, lineage plasticity has recently considered to play a key part in the development of TKI resistance in NSCLC. Despite the functions of IncRNAs in cancer have been extensively studied in the past few years, we are beginning to understand the implications of IncRNA in TKI resistance in NSCLC, particularly in regulating lineage plasticity-mediated drug escape. A better understanding of the deregulated IncRNA involved in lineage plasticity will shed light on the complexity of the molecular alterations underlying TKI resistance. Recently, CRISPR-based screening has successfully identified many cancer-promoting IncRNAs. The simplicity, low cost and flexibility of pooled CRISPR screening brings transcriptome-wide screens within reach of the average molecular oncology laboratory.
We anticipate that future pooled CRISPR screening will be implemented to identify lineage plasticity-related lncRNAs. The current strategies to target lineage plasticity mainly include targeting the epigenetic and transcriptional alterations. However, there remains many challenges ahead to better understand the process. First, the molecular determinants and biomarker for tumor cell phenotypic plasticity upon TKI treatment needs to be better understood. Second, the heterogeneity should be taken into account when targeting the residual tumor cells. Finally, further investigations such as CRISPR screening are required to discover lineage plasticity-related lncRNAs, and use lncRNAs as novel diagnosis and treatment modalities. Overcoming the obstacles will enable us to implement personalized medicine in the treatment of TKI resistance in NSCLC patients.

**Author contributions** TYL wrote the manuscript. CC H prepared all the figures and tables. PQF, HYZ and SW W were involved in the revising of the manuscript, ZFM, QLZ and WJX contributed to the manuscript preparation. RY, JW and LX participated in the design of the manuscript and the revision. All authors read and approved the final manuscript.

**Funding** This work was supported by the National Natural Science Foundation of China (81802277, 81872378, 81802907) and China Postdoctoral Science Foundation (2018M642198), Project of Jiangsu Provincial Medical Talent (ZDRCA2016033).

**Availability of data and materials** All data generated during this study are included in this published article.

**Compliance with ethical standards**

**Conflict of interest** The authors declare no competing interests.

**Consent for publication** All authors reviewed and approved the manuscript.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Hanahan D (2014) Rethinking the war on cancer. Lancet 383(9916):558–563. https://doi.org/10.1016/S0140-6736(13)62226-6

2. Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V (2019) The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer 19(1):9–31. https://doi.org/10.1038/s41568-018-0081-9

3. Rotow J, Bivona TG (2017) Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 17(11):637–658. https://doi.org/10.1038/nrc.2017.84

4. Mayekar MK, Bivona TG (2017) Current landscape of targeted therapy in lung cancer. Clin Pharmacol Ther 102(5):757–764. https://doi.org/10.1002/cpt.810

5. Roesch A (2015) Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene 34(23):2951–2957. https://doi.org/10.1038/ongo.2014.249

6. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sarderys RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA (2016) Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 22(3):262–269. https://doi.org/10.1038/nm.4040

7. Quintanal-Villalonga A, Chan JM, Yu HA, Pe’er D, Sawyers CL, Sen T, Rudin CM (2020) Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-020-0340-z

8. Barkley D, Yanai I (2019) Plasticity and clonality of cancer cell states. Trends Cancer 5(11):655–656. https://doi.org/10.1016/j.trecan.2019.09.002

9. Ramirez M, Rajaram S, Steininger RJ, Ospichuk D, Roth MA, Morinishli LS, Evans L, Ji W, Hsu CH, Thurley K, Wei S, Zhou A, Koduru PR, Posner BA, Wu LF, Altshuler SJ (2016) Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 7:10690. https://doi.org/10.1038/ncomms10690

10. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, Cancer Genome Atlas Research N, Xie W, Yang D (2018) LncRNA EpiGenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell 33(4):706–720. https://doi.org/10.1016/j.ccell.2018.03.006 ((c709))

11. Lee JT (2012) Epigenetic regulation by long noncoding RNAs. Science 338(6133):1435–1439. https://doi.org/10.1126/science.1231776

12. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cooper AK, Akhanfarad S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Minokudusson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26. https://doi.org/10.1126/scitranslmed.3002003

13. Yuan S, Norgard RJ, Stanger BZ (2019) Cellular plasticity in cancer. Cancer Discov 9(7):837–851. https://doi.org/10.1158/2159-8290.CD-19-0015

14. Boumahdi S, de Sauvage FJ (2019) The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. https://doi.org/10.1038/s41573-019-0044-1

15. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheshwaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1):69–80. https://doi.org/10.1016/j.cell.2010.02.027
16. Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Haas NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H (2015) A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene 34(34):4545. https://doi.org/10.1038/onc.2014.432

17. Oser MG, Niederst MJ, Sequist LV, Engelman JA (2015) Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 16(4):e165–172. https://doi.org/10.1016/S1470-2045(14)71180-5

18. Lee JK, Lee J, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, Kim YT, Kim JS, Kim SH, Lee JS, Lee SH, Park K, Ju JL, Jea YK, Chung DH, Park PJ, Kim J, Kim TM, Ju YS (2017) Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol 35(26):3065–3074. https://doi.org/10.1200/JCO.2016.71.9096

19. Marcoux N, Gettinger SN, O’Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Braheimer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Minokududson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd PA, Piotrowska Z, Sequist LV (2019) EGFR-Mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol 37(4):278–285. https://doi.org/10.1200/JCO.2018.10.1585

20. Niederst MJ, Sequist LV, Poirier JT, Merrel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Janne PA, Borger DR, Ramsawamy S, Shioda T, Iafraje AT, Getz G, Rudin CM, Minokududson M, Engelman JA (2015) RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun 6:6377. https://doi.org/10.1038/ncomms7377

21. Tata PR, Rajagopal J (2016) Cellular plasticity: 1712 to the present day. Curr Opin Cell Biol 43:46–54. https://doi.org/10.1016/j.ceb.2016.07.005

22. Davies AH, Beltran H, Zoubaidi A (2018) Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol 15(5):271–286. https://doi.org/10.1038/nruro.2018.22

23. Zakowski MF, Ladanyi M, Kris MG, Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome G (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355(2):213–215. https://doi.org/10.1056/NEJMoa053610

24. Gower A, Hsu WH, Hsu ST, Wang Y, Giaccone G (2016) Antitumor effects of 5-Aza-2′-deoxycytidine in cancer: implications for lineage plasticity-mediated TKI resistance. Clin Cancer Res 19(1):279–290. https://doi.org/10.1158/1078-0432.CCR-12-1558

25. Chung JH, Rho JK, Xu X, Lee JS, Yoon HJ, Lee CT, Choi YJ, Kim HR, Kim CH, Lee JC (2011) Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 73(2):176–182. https://doi.org/10.1016/j.lungcan.2010.11.011

26. Wus WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM, Look AT (2005) Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123(4):641–653. https://doi.org/10.1016/j.cell.2005.09.029

27. Saxena M, Stephens MA, Pathak H, Rangarajan A (2011) Transcript factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2:e179. https://doi.org/10.1038/cddis.2011.61

28. Lu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355(6320):84–88. https://doi.org/10.1126/science.aaah4307

29. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbe DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, Ellis L, Goodrich DW (2017) RB1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355(6320):78–83. https://doi.org/10.1126/science.aah4199

30. Niederst MJ, Engelman JA (2013) Bypass mechanisms of resistance to receptor tyrosine kinase inhibitor in lung cancer. Sci Signal 6(294):re6. https://doi.org/10.1126/scisignal.2004652

31. Li M, Izpisua Belmonte JC (2015) Roles for noncoding RNAs in cell-fate determination and regeneration. Nat Struct Mol Biol 22(1):2–4. https://doi.org/10.1038/nsmb.2946

32. Crea F, Venalainen E, Ci X, Cheng H, Pikor L, Parolia A, Xue H, Nur suede NR, Lin D, Lam W, Collins C, Wang Y (2016) The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics 8(5):721–731. https://doi.org/10.2217/epi.16.6

33. Ramnarine VR, Alshalalfa M, Mo F, Nahavi N, Erho N, Takhar M, Shukin R, Brahimbhatt S, Gawronska A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubaidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC (2018) The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. https://doi.org/10.1093/gigascience/giy050

34. Shibue T, Weinstein RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14(10):611–629. https://doi.org/10.1038/nrcli none.2017.44

35. Gugnoni M, Ciarcocchi A (2019) Long noncoding RNA and epithelial mesenchymal transition in cancer. Int J Mol Sci. https://doi.org/10.3390/ijms20081924

36. Grelet S, Link LA, Howley B, Obellianne C, Palanisamy V, Gangaraju VK, Diehl JA, Howe PH (2017) A regulated PNUTS mRNA to IncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol 19(9):1105–1115. https://doi.org/10.1038/ncb3595

37. Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H, Kong J, Ding K, Shen HM, Wu H, Xia D, Wu Y (2017) Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition
by sponging miR-150-5p. Mol Cancer 16(1):118. https://doi.org/10.1186/s12943-017-0659-9

40. Ge X, Li GY, Jiang L, Jia L, Zhang Z, Li X, Wang R, Zhou M, Zhou Y, Zeng Z, Xiang J, Li J (2019) Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI1 axis. Oncogene 38(16):3061–3076. https://doi.org/10.1038/s41388-018-0645-x

41. Peng W, He D, Shan B, Wang J, Shi W, Zhao W, Peng Z, Luo Q, Duan M, Li B, Cheng Y, Dong Y, Tang F, Zhang C, Duan C (2019) LINCR81507 acts as a competing endogenous RNA of miR-199b-5p to facilitate NSCLC proliferation and metastasis via regulating the CAV1/STAT3 pathway. Cell Death Dis 10(7):533. https://doi.org/10.1038/s41419-019-1740-9

42. Jia Y, Duan Y, Liu T, Wang X, Lv W, Wang M, Wang J, Liu L (2019) LncRNA TTN-AS1 promotes migration, invasion, and epithelial-mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5. Cell Death Dis 10(6):573. https://doi.org/10.1038/s41419-019-1811-y

43. Zhang Q, Li X, Li X, Li X, Chen Z (2018) LncRNA H19 promotes epithelial-mesenchymal transition (EMT) by targeting miR-484 in human lung cancer cells. J Cell Biochem 119(6):4447–4457. https://doi.org/10.1002/jcb.26537

44. Yang QS, Li B, Xu G, Yang SQ, Wang P, Tang HH, Liu YY (2019) Long noncoding RNA LINC00483/microRNA-144 regulates radiosensitivity and epithelial-mesenchymal transition in lung adenocarcinoma by interacting with HOXA10. J Cell Physiol 234(7):11805–11821. https://doi.org/10.1002/jcp.27866

45. Liang R, Xiao G, Wang M, Li X, Li Y, Hui Z, Sun X, Qiu S, Zhang B, Du N, Liu D, Ren H (2018) SNHG6 functions as a competing endogenous RNA to regulate EZF7 expression by sponging miR-26a-5p in lung adenocarcinoma. Biomed Pharmacother 107:1434–1446. https://doi.org/10.1016/j.bjp.2018.09.099

46. Cao Y, Luo X, Ding X, Cui S, Guo C (2018) LncRNA ATB promotes proliferation and metastasis in A549 cells by down-regulation of microRNA-494. J Cell Biochem 119(8):6935–6942. https://doi.org/10.1002/jcb.26894

47. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R (2010) TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107(5):15535–15540. https://doi.org/10.1073/pnas.1009472107

48. Sakai S, Ohhata T, Kitagawa K, Uchida C, Aoshima T, Niida K, Miyazono K, Koinuma D (2018) Long noncoding RNA NORAD regulates transforming growth factor-beta signaling and epithelial-to-mesenchymal transition-like phenotype. Cancer Sci 109(7):2211–2220. https://doi.org/10.1111/cas.13626

49. Terashima M, Tange S, Ishimura A, Suzuki T (2017) MEG3 Long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J Biol Chem 292(1):82–99. https://doi.org/10.1074/jbc.M116.750950

50. Lu L, Luo F, Liu Y, Liu X, Shi L, Lu X, Liu Q (2015) Post-transcriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract. Toxicol Appl Pharmacol 289(2):276–285. https://doi.org/10.1016/j.taap.2015.09.016

51. He R, Zhang FH, Shen N (2017) LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC). Biomed Pharmacother 95:331–338. https://doi.org/10.1016/j.biopha.2017.08.057

52. Chen JH, Zhou LY, Xu S, Zheng YL, Wan YF, Hu CP (2017) Overexpression of lncRNA HOXA11-AS promotes cell epithelial-mesenchymal transition by repressing miR-200b in non-small cell lung cancer. Cancer Cell Int 17:64. https://doi.org/10.1186/s12935-017-0433-7

53. Wu Y, Lyu H, Liu H, Shi X, Song Y, Liu B (2016) Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. Sci Rep 6:31093. https://doi.org/10.1038/srep31093

54. Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ, Chen JF, Zhang EB, De W, Wang ZX (2014) Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer 13:68. https://doi.org/10.1186/1476-4598-13-68

55. Lu Z, Li Y, Wang J, Che Y, Sun S, Huang J, Chen Z, He J (2017) Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF-kappaB/NF pathway. J Exp Clin Cancer Res 36(1):54. https://doi.org/10.1186/s13046-017-0518-0

56. Hao Y, Yang X, Zhang D, Luo J, Chen R (2017) Long noncoding RNA LINC01186, regulated by TGF-beta/SMA3D, inhibits migration and invasion through epithelial-mesenchymal-transition in lung cancer. Gene 608:1–12. https://doi.org/10.1016/j.gene.2017.01.023

57. Balaban NQ, Gerdes K, Lewis K, McKinney JD (2013) A prob lem of persistence: still more questions than answers? Nat Rev Microbiol 11(8):587–591. https://doi.org/10.1038/nrmicro3076

58. Sanchez-Danes A, Larsimont JC, Liagre M, Munoz-Couselo E, Lapouge G, Brisebarre A, Dubois C, Suppa M, Sukumaran V, Del Marmol V, Tabernero J, Blanpain C (2018) A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature 562(7727):434–438. https://doi.org/10.1038/s41586-018-0603-3

59. Schmitt AM, Chang HY (2016) Long noncoding RNAs in cancer pathways. Cancer Cell 29(4):452–463. https://doi.org/10.1016/j.ccell.2016.03.010

60. Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K, Ward AJ, Raj A, Lee JT, Sharp PA, Jacks T (2014) Long non-coding RNA LINC-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell 54(5):777–790. https://doi.org/10.1016/j.molcel.2014.04.025

61. Schmitt AM, Garcia JT, Hung T, Flynn RA, Shen Y, Qu K, Payumo AY, Peres-da-Silva A, Broz DK, Baum R, Guo S, Chen JK, Attard L, Chang HY (2016) An inducible long noncoding RNA amplifies DNA damage signaling. Nat Genet 48(11):1370–1376. https://doi.org/10.1038/ng.3673
66. Jiang J, Gu Y, Liu J, Wu R, Fu L, Zhao J, Guan Y (2016) Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs. Lung Cancer 102:101–107. https://doi.org/10.1016/j.lungcan.2016.10.015

67. Montes M, Nielsen MM, Maglieri G, Jacobsen A, Hojfeldt J, Agrawal-Singh S, Hansen K, Helin K, van de Werken HJG, Pedersen JS, Lund AH (2015) The IncRNA MIR31HG regulates p16(INK4A) expression to modulate senescence. Nat Commun 6:6967. https://doi.org/10.1038/ncomms7967

68. Yu W, Gius D, Onyango P, Muldoon-Jacob K, Karp J, Feinberg AP, Cui H (2008) Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451(7175):202–206. https://doi.org/10.1038/nature06468

69. Sun Q, Tripathi V, Yoon JH, Singh DK, Hao Q, Min KW, Davila S, Zealy RW, Li XL, Polycarpou-Schwarz M, Lehrmann E, Zhang Y, Becker KG, Freier SM, Zhu Y, Diederichs S, Prasanth SG, Lal A, Gorospe M, Prasanth KV (2018) MIR100 host gene-encoded IncRNAs regulate cell cycle by modulating the interaction between HuR and its target mRNAs. Nucleic Acids Res 46(19):10405–10416. https://doi.org/10.1093/nar/gky696

70. Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, Xu X, Xu T, Hu X, Sun L, He B, Pan Y, Sun H, Wang S (2018) The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer 17(1):141. https://doi.org/10.1186/s12943-018-0894-x

71. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cytry J, Marotz C, Giannopoulou E, Chakravarti BH, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Shafiee M, Semnani S, Vasei M, Mowla SJ (2014) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22(3):298–305. https://doi.org/10.1038/nm.4045

73. Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cytry J, Shafiee M, Noorzad Z, MacDonald T, Cheung C, Yu KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS (2016) N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell 30(4):563–577. https://doi.org/10.1016/j.ccell.2016.09.005

74. Kim JS, Ibasa A, Fischer MM, Cancilla B, O’Young G, Cristea S, Luca VC, Yang D, Jahchan NS, Hamard C, Antoine M, Wislez M, Kong C, Cai J, Liu YW, Kapoun AM, Garcia KC, Hoey T, Marurriel CL, Sage J (2017) Intratumoral heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 545(7654):360–364. https://doi.org/10.1038/nature22323

75. Santos M, Martinez-Fernandez M, Duenas M, Garcia-Escudero R, Alfaya B, Villacampa F, Saiz-Ladera C, Costa C, Oteo M, Duarte J, Martinez V, Gomez-Rodriguez MJ, Martin ML, Fernandez M, Viator P, Morcillo MA, Sage J, Castellano D, Rodriguez-Peralto JL, de la Rosa F, Paramio JM (2014) In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.

Cancer Res 74(22):6565–6577. https://doi.org/10.1158/0008-5472.CAN-14-1218

80. Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jamaica R, Niip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubibehi A (2017) The Master neural transcription factor BRN2 Is androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov 7(1):54–71. https://doi.org/10.1158/2159-8290.CD-15-1263

81. Sakaeda M, Sato H, Iishi J, Miyata C, Kamma H, Shishido-Hara Y, Shimoyamada H, Fujiwara M, Endo T, Tanaka R, Kondo H, Goya T, Aoki I, Yazawa T (2013) Neural lineage-specific homeobox protein BRN2 is directly involved in TTF1 expression in small-cell lung cancer. Lab Invest 93(4):408–421. https://doi.org/10.1038/labinvest.2013.2

82. Chen C, NoTKIns AL, Lan MS (2019) Insulinoma-associated-1: from neuroendocrine tumor marker to cancer therapeutics. Mol Cancer 17(8):1597–1604. https://doi.org/10.1186/s12943-018-0894-x

83. Ahmad A, Strobbeucker S, Tufarelli C, Sottile V (2017) Expression of a SOX1 overlapping transcript in neural differentiation and cancer models. Cell Mol Life Sci 74(22):4245–4258. https://doi.org/10.1007/s00018-017-2580-3

84. Saghaehian Jazi M, Samaei NM, Ghanie M, Shadmehr MB, Mowla SJ (2016) Identification of new SOX2OT transcript variants highly expressed in human cancer cell lines and down regulated in stem cell differentiation. Mol Biol Rep 43(2):65–72. https://doi.org/10.1007/s11033-015-3939-x

85. Shahryari A, Jazi MS, Samaei NM, Mowla SJ (2015) Long noncoding RNA SOX2OT: expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis. Front Genet 6:196. https://doi.org/10.3389/fgene.2015.00196

86. Shahryari A, Rafiee MR, Fouani Y, Oliae NA, Samaei NM, Shafee M, Semnani S, Vasei M, Mowla SJ (2014) Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coexpressed with SOX2 and OCT4 in esophageal squamous cell carcinoma. Stem Cells 32(1):126–134. https://doi.org/10.1002/stem.1542

87. Kim JT, Liu C, Zaytseva YY, Weiss HL, Townsend CM Jr, Evers BM (2015) Neurotensin, a novel target of Wnt/beta-catenin pathway, promotes growth of neuroendocrine tumor cells. Int J Cancer 136(6):1475–1481. https://doi.org/10.1002/ijc.29123

88. Meder L, Konig K, Ozretic L, Schluthies AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, Buhl T, Hartmann W, Wolf J, Merkelbach-Bruse S, Eilers M, Perner S, Heukamp LC, Buettner R (2016) NOTCH, ASC1L1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer 138(4):927–938. https://doi.org/10.1002/ijc.29835

89. Tenjin Y, Kudoh S, Kubota S, Yamada T, Matsuoka S, Ichimura T, Kohrogi H, Sashida G, Sakagami T, Ito T (2019) ASC1L1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology. Lab Invest 99(11):1622–1635. https://doi.org/10.1038/s41374-019-0277-y
90. Osada H, Tomida S, Yatabe Y, Tatematsu Y, Takeuchi T, Murakami H, Kondo Y, Sekido Y, Takahashi T (2008) Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. Cancer Res 68(6):1647–1655. https://doi.org/10.1158/0008-5472.CAN-07-5039

91. Rong L, Zhao R, Lu J (2017) Highly expressed long non-coding RNA FOXD2-AS1 promotes non-small cell lung cancer progression via Wnt/beta-catenin signaling. Biochem Biophys Res Commun 484(3):586–591. https://doi.org/10.1016/j.bbrc.2017.01.141

92. Shi SL, Zhang ZH (2019) Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/beta-catenin pathway. Neoplasma 66(5):756–765. https://doi.org/10.14199/neo_2018_1812880

93. Guan H, Zhu T, Wu S, Liu S, Liu B, Wu J, Cai J, Zhu X, Zhang X, Zeng M, Li J, Song E, Li M (2019) Long non-coding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/beta-catenin signaling. Proc Natl Acad Sci USA 116(28):14019–14028. https://doi.org/10.1073/pnas.1900977116

94. Jiang P, Xu H, Xu C, Chen A, Chen L, Zhou M, Haq IU, Wu X, Mariyam Z, Feng Q (2018) NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Chem Biol Interact 294:154–161. https://doi.org/10.1016/j.chembiol.2018.07.001

95. Sun SJ, Lin Q, Ma JX, Shi WW, Yang B, Li F (2017) Long non-coding RNA NEAT1 acts as oncogene in NSCLC by regulating the Wnt signaling pathway. Eur J Med Pharmacol Sci 21(3):504–510

96. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY (2005) IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289(3):L446-453. https://doi.org/10.1152/ajplung.00089.2005

97. Liu L, Liu L, Lu S (2019) lncRNA H19 promotes viability and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-29b-3p and modifying STAT3. Int J Oncol 54(3):929–941. https://doi.org/10.3892/ijo.2019.4695

98. Li S, Mei Z, Hu HB, Zhang X (2018) The lncRNA MALAT1 contributes to non-small cell lung cancer development by modulating miR-124/STAT3 axis. J Cell Physiol 233(9):6679–6688. https://doi.org/10.1002/jcp.26252

99. Huang Z, Lei W, Hu HB, Zhang H, Zhu Y (2018) H19 promotes non-small-cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR-17. J Cell Physiol 233(10):6768–6776. https://doi.org/10.1002/jcp.26530

100. Wang Y, Han D, Pan L, Sun J (2018) The positive feedback between lncRNA TNK2-AS1 and STAT3 enhances angiogenesis in non-small cell lung cancer. Biochem Biophys Res Commun 507(1–4):185–192. https://doi.org/10.1016/j.bbrc.2018.11.004

101. Chen X, Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 18(2):99–115. https://doi.org/10.1038/s41573-018-0004-1

102. Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, Yin R (2019) Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol 12(1):86. https://doi.org/10.1186/s13045-019-0770-1

103. Choi C, Shin YS, Kim C, Choi SJ, Lee J, Kim SY, Cho YB, Kim J (2015) Crotstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. Onco Targets Ther 8:3665–3678. https://doi.org/10.2147/OTT.S89659

104. Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Nisho U, Umemura S, Matsumoto S, Ohmatsu H, Iida S, Nimi A, Nagai K, Ohe Y, Ochiai A (2015) Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res 21(3):642–651. https://doi.org/10.1158/1078-0432.CCR-14-0846

105. Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernandez-Perez D, Isella C, Granchi C, Minutofo F, Sottile A, Comoglio PM, Medic I, Pietrantonio F, Volante M, Pasini D, Chiarugi P, Giordano S, Corso S (2018) Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab 28(6):848–865. https://doi.org/10.1016/j.cmet.2018.08.006 ((e846))

106. Suzuki E, Yamazaki S, Naito T, Hashimoto H, Okubo S, Udagawa H, Goto K, Tsaboi M, Ochiai A, Ishii G (2019) Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancer-associated fibroblasts with EGFR-TKI resistance-promoting phenotype: A study of 18 cases of cancer-associated fibroblasts. Pathol Int 69(8):472–480. https://doi.org/10.1111/pin.121838

107. Engeljan PA, Zeljnullahov K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043. https://doi.org/10.1126/science.1141478

108. Karachaliou N, Codony-Servat J, Teixido C, Pilotto S, Drzosdzyk A, Codony-Servat C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Gervais R, Massuti B, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Gonzalez-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramirez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, Lopez-Vivanco G, Miguel Sanchez J, Vergnenegre A, Sanchez Hernandez JJ, Sperduti I, Bri A, Rosell R (2015) BIM and mTORT expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep 5:17499. https://doi.org/10.1038/srep17499

109. Wang Y, Zhang T, Guo L, Ren T, Yang Y (2019) Stromal extra-cellular matrix is a microenvironmental cue promoting resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. Int J Biochem Cell Biol 106:96–106. https://doi.org/10.1016/j.biocel.2018.11.001

110. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomonides CC, June CH, Pure E, Alberda SM (2014) Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2(2):154–166. https://doi.org/10.1158/2326-6066.CIR-13-0027

111. Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou W, Wang J, Yang B, Zhao Y, Rao Z, Gao J (2014) M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. Med Oncol 31(8):127. https://doi.org/10.1007/s12032-014-0127-0

112. Choi H, Sheng J, Gao D, Li F, Durrans A, Ryu S, Lee SB, Narula N, Rafii S, Elemento O, Altorki NK, Wong ST, Mittal V (2015) Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model. Cell Rep 10(7):1187–1201. https://doi.org/10.1016/j.celrep.2015.01.040

113. Che D, Zhang S, Jing Z, Shang L, Jin S, Liu F, Shen J, Li Y, Hu J, Meng Q, Yu Y (2017) Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/beta-catenin signalling pathway. Mol Immunol 90:197–210. https://doi.org/10.1016/j.molimm.2017.06.018

114. Sun Y, Xu J (2019) TCF-4 Regulated IncRNA-XIST promotes M2 polarization of macrophages and is associated with
Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI...
137. Esposito R, Bosch N, Lanzos A, Polidori T, Pulido-Quetglas C, Johnson R (2019) Hacking the cancer genome: profiling therapeutically actionable long non-coding RNAs using CRISPR-Cas9 screening. Cancer Cell 35(4):545–557. https://doi.org/10.1016/j.ccell.2019.01.019

138. Goyal A, Myacheva K, Gross M, Klingenberg M, Duran Arque B, Diederichs S (2017) Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic Acids Res 45(3):e12. https://doi.org/10.1093/nar/gkw883

139. Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, Chiari R, Westeel V, Poudenx M, Letreut J, Gervais R, Osman G, Girard N, Toffart AC, Novello S, Moro-Sibilot D (2019) A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics. J Thorac Oncol 14(1):130–134. https://doi.org/10.1016/j.jtho.2018.08.2028

140. Qiu M, Xia W, Chen R, Wang S, Xu Y, Ma Z, Xu W, Zhang E, Wang J, Fang T, Hu J, Dong G, Yin R, Wang J, Xu L (2018) The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma. Cancer Res 78(11):2839–2851. https://doi.org/10.1158/0008-5472.CAN-17-2808

141. Sheridan C (2013) First Axl inhibitor enters clinical trials. Nat Biotechnol 31(9):775–776. https://doi.org/10.1038/nbt0913-775a

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.